肌醇补充预防多囊卵巢综合征妊娠并发症:一项随机临床试验
这项在荷兰13家医院开展的双盲、安慰剂对照随机试验纳入妊娠8至16周的多囊卵巢综合征孕妇,比较每日两次肌醇2 g联合叶酸0.2 mg与单纯叶酸0.2 mg至分娩的效果。主要复合结局为妊娠期糖尿病、子痫前期或37周前早产,肌醇组发生率25.0%(56例),安慰剂组26.8%(61例),相对风险0.93(95%CI 0.68-1.28;P=0.67),未降低主要复合结局发生率。
要点
- 肌醇组主要复合结局发生率为25.0%(56例),安慰剂组为26.8%(61例)。
- 相对风险0.93(95%CI 0.68-1.28;P=0.67),未达统计学显著。
- 妊娠期补充肌醇未降低多囊卵巢综合征患者主要复合结局发生率。
核心结论
- 妊娠期补充肌醇未降低多囊卵巢综合征患者妊娠期糖尿病、子痫前期或早产的复合结局发生率。
研究设计与样本
- 双盲、安慰剂对照、随机试验,在荷兰13家医院开展。
- 纳入妊娠8至16周的多囊卵巢综合征孕妇,2019年6月至2023年3月入组,最终随访于2023年12月27日完成,分析于2024年7月进行。
- 共464名参与者,按1:1随机分配至肌醇2 g联合叶酸0.2 mg每日两次组(n=230)或匹配安慰剂联合叶酸0.2 mg组(n=234),直至分娩。
主要发现
- 参与者平均(SD)年龄31.5(3.8)岁;18名参与者(3.9%)报告为亚洲种族,395名(86.1%)报告为白人种族。
- 基线时肌醇组生化高雄激素血症患病率高于安慰剂组(29.0%[53/180] vs 18.5%[37/193])。
- 主要结局事件在肌醇组发生率25.0%(n=56),安慰剂组26.8%(n=61),相对风险0.93(95%CI 0.68-1.28;P=0.67)。
关键数值与推荐
- 主要结局为妊娠期糖尿病、子痫前期或早产(妊娠37周前)的复合结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Pregnant individuals with polycystic ovary syndrome (PCOS) present with a higher risk of pregnancy complications, including gestational diabetes, preeclampsia, and preterm birth. Myo-inositol supplementation may reduce these risks. OBJECTIVE: To determine whether daily supplementation with myo-inositol during pregnancy among individuals with PCOS reduces the risk of a composite outcome of gestational diabetes, preeclampsia, and preterm birth. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled, randomized trial was conducted at 13 hospitals in the Netherlands. Pregnant individuals with PCOS who were between 8 and 16 weeks' gestation were enrolled between June 2019 and March 2023. Final follow-up was complete on December 27, 2023. Analyses were conducted July 2024. INTERVENTIONS: Participants were randomized on a 1:1 basis to receive sachets with either myo-inositol, 2 g, with 0.2 mg of folic acid twice daily (n = 230) or matching placebo with 0.2 mg of folic acid only (n = 234) until delivery. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of gestational diabetes, preeclampsia, or preterm birth (before 37 weeks' gestation). RESULTS: Among 464 participants, the mean (SD) age was 31.5 (3.8) years; 18 participants (3.9%) reported Asian race and 395 (86.1%) reported White race. The prevalence of biochemical hyperandrogenism was higher at baseline in the myo-inositol group than the placebo group (29.0% [53 of 180] vs 18.5% [37 of 193]). A primary outcome event occurred in 25.0% (n = 56) of participants in the myo-inositol group and 26.8% (n = 61) in the placebo group (relative risk, 0.93 [95% CI, 0.68-1.28]; P = .67). CONCLUSIONS AND RELEVANCE: Myo-inositol supplementation during pregnancy did not reduce the incidence of a composite of gestational diabetes, preeclampsia, or preterm birth in patients with PCOS. TRIAL REGISTRATION: onderzoekmetmensen.nl Identifier: NL67329.078.18.
引用
- van der Wel AWT, Frank CMC, Bout-Rebel R, et al. Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial. JAMA. 2025. PMID: 40920401. doi:10.1001/jama.2025.13668
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。